Oral vitamin D supplements at a dose of at least 400 international units per day are associated with a reduced risk of bone fractures in older adults, according to results of a meta-analysis published in the March 23 issue of Archives of Internal Medicine.
"The anti-fracture benefits of vitamin D have been questioned by several recent trials," the authors write, adding that "factors that may obscure a benefit of vitamin D are low adherence to treatment, low dose of vitamin D or the use of less potent ergocalciferol (vitamin D2)."
The scientists performed a meta-analysis on 12 previously-published clinical trials involving 42,279 participants and found that vitamin D supplements decreased the risk of non-vertebral fractures by 14% and of hip fractures by 9%. The authors then pooled the results of only nine trials in which subjects received doses of more than 400 international units per day. At this higher dosage, vitamin D reduced non-vertebral fractures by 20% and hip fractures by 18%. Lower doses did not cut the risk of either fracture type. A greater reduction was also seen among trial participants whose blood levels of 25-hydroxyvitamin D - a commonly used measure of blood vitamin D levels - achieved a greater increase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze